151 related articles for article (PubMed ID: 32699060)
1. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma.
Foo T; Tapia Rico G; Brown MP
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32699060
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.
Ben-Betzalel G; Steinberg-Silman Y; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2019 Feb; 108():61-68. PubMed ID: 30648631
[TBL] [Abstract][Full Text] [Related]
3. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
7. Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate.
Parekh V; Gangadhar T; Kreider KL; Elenitsas R; Chu EY
JAMA Dermatol; 2017 Jul; 153(7):719-721. PubMed ID: 28445579
[No Abstract] [Full Text] [Related]
8. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
9. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
[TBL] [Abstract][Full Text] [Related]
11. Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
Grogan N; Swami U; Bossler AD; Zakharia Y; Milhem M
Melanoma Res; 2018 Dec; 28(6):600-604. PubMed ID: 30086073
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report.
Ma Q; Yang L; Gu F
Medicine (Baltimore); 2021 Jan; 100(1):e24018. PubMed ID: 33429766
[TBL] [Abstract][Full Text] [Related]
13. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Maity A; Mick R; Huang AC; George SM; Farwell MD; Lukens JN; Berman AT; Mitchell TC; Bauml J; Schuchter LM; O'Hara M; Lin LL; Demichele A; Christodouleas JP; Haas NB; Patsch DM; Hahn SM; Minn AJ; Wherry EJ; Vonderheide RH
Br J Cancer; 2018 Nov; 119(10):1200-1207. PubMed ID: 30318516
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
16. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
[TBL] [Abstract][Full Text] [Related]
18. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.
Ibrahim T; Mateus C; Baz M; Robert C
Cancer Immunol Immunother; 2018 Oct; 67(10):1571-1578. PubMed ID: 30056599
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
Marjanska A; Galazka P; Marjanski M; Wysocki M; Styczynski J
Anticancer Res; 2019 Jul; 39(7):3945-3947. PubMed ID: 31262925
[TBL] [Abstract][Full Text] [Related]
20. PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach.
Proietti I; Filippi L; Michelini S; Porta N; Bernardini N; Mambrin A; Tolino E; Pacini L; Rosa P; Calogero A; Romeo G; Di Cristofano C; Petrozza V; Bagni O; Skroza N; Potenza C
Clin Ter; 2020; 171(4):e283-e287. PubMed ID: 32614358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
